These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7499447)

  • 81. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.
    Canobbio L; Rubagotti A; Miglietta L; Cannata D; Curotto A; Amoroso D; Boccardo F
    J Cancer Res Clin Oncol; 1995; 121(12):753-6. PubMed ID: 7499447
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
    van Herpen CM; De Mulder PH
    Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Statistical aspects of the analysis of data from retrospective studies of disease.
    MANTEL N; HAENSZEL W
    J Natl Cancer Inst; 1959 Apr; 22(4):719-48. PubMed ID: 13655060
    [No Abstract]   [Full Text] [Related]  

  • 88. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
    Rosenberg SA; Lotze MT; Yang JC; Topalian SL; Chang AE; Schwartzentruber DJ; Aebersold P; Leitman S; Linehan WM; Seipp CA
    J Natl Cancer Inst; 1993 Apr; 85(8):622-32. PubMed ID: 8468720
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
    Buter J; Sleijfer DT; van der Graaf WT; de Vries EG; Willemse PH; Mulder NH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):16-21. PubMed ID: 8284687
    [No Abstract]   [Full Text] [Related]  

  • 90. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
    Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
    Oncology; 1994; 51(1):59-62. PubMed ID: 8265104
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.
    Vuoristo M; Jantunen I; Pyrhönen S; Muhonen T; Kellokumpu-Lehtinen P
    Eur J Cancer; 1994; 30A(4):530-2. PubMed ID: 8018415
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha.
    Fosså SD; Kramar A; Droz JP
    Eur J Cancer; 1994; 30A(9):1310-4. PubMed ID: 7999419
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Renal cell cancer: is there long-term survival advantage from cytokine treatment?
    Oliver RT
    Eur J Cancer; 1994; 30A(9):1214-6. PubMed ID: 7999400
    [No Abstract]   [Full Text] [Related]  

  • 94. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.
    Jones M; Philip T; Palmer P; von der Maase H; Vinke J; Elson P; Franks CR; Selby P
    Cancer Biother; 1993; 8(4):275-88. PubMed ID: 7804369
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Reporting results of cancer treatment.
    Miller AB; Hoogstraten B; Staquet M; Winkler A
    Cancer; 1981 Jan; 47(1):207-14. PubMed ID: 7459811
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
    West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
    N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
    N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
    [TBL] [Abstract][Full Text] [Related]  

  • 98. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.
    Rosenberg SA; Lotze MT; Mulé JJ
    Ann Intern Med; 1988 Jun; 108(6):853-64. PubMed ID: 3285747
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.
    Elson PJ; Witte RS; Trump DL
    Cancer Res; 1988 Dec; 48(24 Pt 1):7310-3. PubMed ID: 3056613
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.